Abstract

INTRODUCTION

Multiple Myeloma (MM) is a common hematological malignancy and various factors affect survival. Uric acid (UA) is an easily and quickly accessible laboratory test. UA has been found to affect prognosis and survival in many hematological diseases and its impact on myeloma is not widely investigated.

METHODS

Our retrospective study includes 106 MM patients between 2014 and 2021. The influence of UA level at diagnosis on treatment outcomes and survival of patients who received autologous stem cell transplantation (ASCT) was investigated.

RESULTS

The mean UA at diagnosis was 6.05 mg/dL, and 38.7% of our cohort relapsed after a median of 30 months of follow-up, with 22.7 percent dead. In survival analysis, the level of UA did not significantly differ in both progression-free survival (PFS) and overall survival (OS) (HR, 1.067; 95% CI, 0.947-1.202; p=0.290, HR, 0.941; 95% CI, 0.791-1.121; p=0.497, respectively).

DISCUSSION AND CONCLUSION

In our study, regardless of the cut-off value for the UA level at the time of diagnosis, the cut-off value had no impact on PFS or OS in MM patients who received ASCT.